| ID: | 106 | |
|---|---|---|
| Name: | Compound 106 | |
| Description: | Original numeration in publication: 8 | |
| Labels: | Training_set, Quinoline, and, isatin | |
| CAS: | ||
| InChi Code: | InChI=1S/C23H19N3O6S/c1-31-16-5-3-15(4-6-16)24-20(27)12-26-22(29)19(33-23(26)30)11-14-9-13-10-17(32-2)7-8-18(13)25-21(14)28/h3-11H,12H2,1-2H3,(H,24,27)(H,25,28)/b19-11- |
pIC50: Negative logarithm of half-maximal inhibitory concentration [-log(uM)]
| Value | Source or prediction |
|---|---|
| 6.73 |
Elkaeed, E. B.; Taghour, M. S.; Mahdy, H. A. a. E., W. M.; El-Deeb, N. M.; Kenawy, A. M.; A Alsfouk, B.; Dahab, M. A.; Metwaly, A. M. a. E., I. H.; El-Zahabi, M. A. New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. J. Enzyme Inhib. Med. Chem. 2022, 37, 2191–2205. https://doi.org/10.1080/14756366.2022.2110869 |
| 6.80258 |
Eq1: VEGFR-2 inhibition (Data used to train model) |